This study allows increase the level of objective assessment of the beginning and course of influenza and other ARVIs in outpatient practice, to predict their course and outcome, and to improve the treatment.

The purpose of study is Evaluation of Clinical and Immunological effects of using Camelyn in Periodontology. Materials and methods: We have studied clinical and immunological features of 20 patients with periodontitis between ages 20 and 60 (these patients were from the dental clinic Mitra). CPI index has been studied dynamically -before treatment, after treatment, 6 months and 1 year later. Treatment included scaling and root planning. During these 2 weeks we have used 10 ml of Camelyn 25 percent solution for rinsing. We applied it for 2 minutes. We checked cellular and humoral immunity in peripheral blood stem. Lysozyme activation was determined. Results: After treatment, the median CPI index was significantly reduced. After 6 months and a year of treatment it was insignificantly increased, but in comparison with the initial CPI it was remained significantly less.Before starting treatment Interferon and the phagocytic system was significantly lowered, also amount of TLymphocytes, but the amount of T suppressors was increased; After the treatment mentioned above the parameters were significantly increased, although in comparison with the standard it still was low. After the treatment the amount of T-suppressors was significantly decreased.Saliva significantly showed a reduction of the amount of lysozyme and sIgA Before treatment IgG was significantly lower and IgM higher. After the treatment all kinds of Immunoglobulins were almost the same; Conclusion: Including Camelyn in European Scientific Journal May 2017 edition Vol.13, No.15 ISSN: 1857 -7881 (Print) e -ISSN 1857 2 traditional treatment of periodontitis promotes immune response activation and it has a positive influence on a clinical picture -it improves periodontitis clinical features and significantly reduces CPI index.

The purpose of this study was to test the combined module for water disinfection for the presence of an antimicrobial (Staphylococcus aureus) activity in a specific liquid environment. A portable module for drinking and wastewater disinfection (patented in Georgia, GE P 2013 5987B), was taken as an analog.For the first time on the actual material (generator + infected saline) we revealed a reliable bactericidal effect on staphylococci. The intensity of the neutralization of staphylococci mainly depended on the exposure time of the generator, as well as on the initial dose of microbes, i.e., the degree of water pollution.The bactericidal effect of the module was confirmed not only in saline but also in distilled water and household tap water. We emphasize that in this experiment the non-sterile liquid was used for the first time. It also turned out that a 60-second exposure provided reliable antimicrobial protection of the liquids used within the first 6 days of the experiment. Однойиз актуальных задач при обеззараживании питьевой воды, а также промышленных и бытовых стоков, является применение технологии, не использующей химические реагенты, т.е. технологии, не приводящей к образованию токсичных соединений. Известно множество способов обеззараживания воды и биологических жидкостей. Самыми эффективными из нихявляются хлорирование, ультрафиолетовое и инфракрасное облучение, воздействие ионов серебра или меди, озонирование. Однако у каждого из них имеется один общий, существенный недостаток -неполное уничтожение патогенной микрофлоры даже при длительном воздействии. Уже доказано, что хлорирование воды приводит к образованию опасных побочных продуктов. Анализ альтернативных хлорированию методов дезинфекции воды показал, что все окислительные технологии обеззараживания приводят к формированию тех или иных побочных продуктов, большинство из которых представляют опасность для здоровья людей. Более того, следует учитывать наметившееся в последнее время повышение устойчивости микрофлоры к воздействию хлора, озона и ультрафиолета. Микробиологи ведущих научных центров Америки Азии и Европы показывают в своих отчетах, что за последние 15-20 лет устойчивость патогенной микрофлоры повысилась к хлору, озону и

Objective - assessment of the influence of the start time of antiviral therapy of acute respiratory viral infection (ARVI) and influenza on dynamics of clinical symptoms and outcome of the disease. Material and methods.The data on 18,946 patients aged 18 to 93 years with previously established clinical diagnosis of ARVI or influenza were obtained and analyzed in the framework of an international multicenter open prospective observational study. The patients were divided into 2 groups: those in the control group received symptomatic treatment without the use of antiviral drugs and patients of group 1 (main group) were given the antiviral drug Kagocel a component of combined therapy. The clinical symptoms, bacterial aggravations, efficacy and safety of prescribed therapy (including antibiotics) were assessed. Results. About a quarter of patients (23.2%) with ARVI and influenza did not seek professional medical help with in the first 24-48 hours after onset of the disease and started treatment on the 3rd day or later. The most common symptom of ARVI or influenza in the first 24-48 hours was hyperthermia that was followed during the next 72 hours or more (in the absence of adequate treatment) by other symptoms, such as coughing the severity of which correlated with the development of bacterial aggravations most often diagnosed on day 5. Administration of interferon inducer Kagocel resulted infaster normalization of body temperature than in the control group regardless of the time of onset of drug administration (both at early and late treatment start time). Therapy with Kagocel led to significant regression of the clinical symptoms of the disease as early as days 2 and 3 with the reduction of the frequency of bacterial aggravations from 13% to 7.9%. The frequency of complete recovery by the 3rd visit was 70.8% in the control group and 77.9% in the main group. The study demonstrated the inexpediency of prophylactic antibiotic treatment for ARVI and influenza (complete recovery rate decreased by 6%) as well as the ambiguity of positive antibiotic effectsonthe outcomeof complications (complete recovery only in 57.7% cases vs 77.4% in the absence of antibiotics). Conclusion. The absence of antiviral treatment for ARVI and influenza is a wrong tactic leading to prolongation of the disease and increased frequency of aggravations. The earlier the antiviral treatment starts, the milder the symptoms are, the lower the aggravation rate is and the earler complete recovery comes. It was shown on a large cohort of patients that administration of antiviral drug Kagocel is effective in case of both the early (24-72 hours after the onset of the disease) and late (72 hours and later) beginning of the treatment.